Clinical trials
Fatty Liver Disease clinical trials
Below are recruiting fatty liver disease clinical trials, each written for real people, not researchers. We’re tracking 188 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06798948RecruitingPhase 2
Can a mix of herbs improve mild fatty liver?
This study is testing if a combination of four herbs (artichoke, milk thistle, turmeric, and licorice root) can help people with non-alcoholic mild to moderate fatty liver disease (also called metabolic-associated fatty liver disease). It's a randomized trial, meaning participants are assigned to either the herbal mix or a comparison group. This may offer a natural option to support liver health.
Hangzhou, Select...Ages 18–65 - NCT06802731Recruiting
Testing a tool to measure liver inflammation in NAFLD
This trial studies a device called LivQ-box to see if it can accurately measure liver inflammation in people with nonalcoholic fatty liver disease (NAFLD). It compares the device's results to a liver biopsy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06803108Recruiting
Pyramidal vs continuous exercise for fatty liver
This study compares two exercise programs to see which works better for people with fatty liver disease and obesity. It may help improve liver health through different workout styles.
GizaAges 37–51 - NCT06814600Recruiting
Fatty liver study in inflammatory bowel disease patients
This study checks how often people with Crohn's or ulcerative colitis also have fatty liver disease. It uses a painless scan to measure liver stiffness and fat. If you have IBD, you may join to help researchers learn about the link between these conditions.
BrusselsAges 18 years+ - NCT06819917Recruiting
Liver fibrosis test study for fatty liver disease
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
CopenhagenAges 18–75 - NCT06863376RecruitingPhase 2
Carbocisteine for fatty liver disease: safety and benefit study
This study tests a medicine called carbocisteine to see if it can help treat nonalcoholic fatty liver disease (NAFLD). If you have a fatty liver and no other liver or kidney conditions, this trial may explore whether this drug is safe and effective for you.
TantaAges 18–65 - NCT06873165Recruiting
Gut bacteria treatment for fatty liver disease
This study tests whether a specially designed gut bacteria treatment can help people with fatty liver disease and related health issues like high blood sugar, high cholesterol, or high blood pressure. It aims to see if the treatment is safe and improves liver health.
TaipeiAges 18–70 - NCT06883578Recruiting
Effect of a low valine diet on body weight and metabolism
This trial studies if a diet low in valine, a building block of protein, can help people with excess weight lose weight and improve their metabolic health. It may offer an alternative approach for weight loss.
Shanghai, Shanghai MunicipalityAges 16–80 - NCT06939569Recruiting
Studying fatty liver disease in people with inflammatory bowel disease
This study looks at how common non-alcoholic fatty liver disease is in people with inflammatory bowel disease (Crohn's or colitis). Researchers want to learn more about the link between the two conditions.
ShanghaiAges 18 years+ - NCT06989723RecruitingPhase 4
Pioglitazone and empagliflozin for fatty liver in type 2 diabetes
This trial tests two diabetes pills (pioglitazone and empagliflozin) to see if they can reduce liver fat in people with type 2 diabetes and fatty liver disease. It may help if your diabetes is not well controlled and you have a fatty liver confirmed by a special ultrasound scan.
Seongnam-siAges 20 years+ - NCT07068191Recruiting
Gepaktiv vs other drugs for fatty liver with enlarged liver
This study tests a new drug, Gepaktiv, compared to two other treatments (UDCA and ademetionine) for people with metabolic fatty liver disease who also have an enlarged liver. You may be able to join if you meet specific test results showing moderate liver fat and scarring.
Tyumen, Tyumen OblastAges 18–65 - NCT07070362Recruiting
Digital early warning system for lung injury after liver surgery
This trial tests a digital early warning system to detect acute lung injury after liver surgery. It may help doctors catch breathing problems early so they can treat them faster.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07083336Recruiting
Diet study for type 2 diabetes with fatty liver disease
This trial tests a specific medical nutrition therapy diet to see if it can reduce liver fat and improve blood sugar control in people with type 2 diabetes and nonalcoholic fatty liver disease. It may help you manage both conditions with a dietary approach.
Yichang, HubeiAges 18 years+ - NCT07086989Recruiting
Heart health study for kids with chronic conditions
This study looks at heart disease risk in children and young adults (ages 6-25) with long-term health conditions like certain heart, kidney, or diabetes disorders. The goal is to better understand and manage heart risks early.
BudapestAges 6–25 - NCT07093346Recruiting
Pectin supplement for fatty liver disease
This study tests whether a pectin supplement (a fiber found in fruits) can reduce inflammation and improve liver and metabolic health in people with fatty liver disease (MASLD). You might be eligible if you have MASLD, a healthy weight range, and can avoid certain medications and foods.
NottinghamAges 18 years+ - NCT07122700Recruiting
Better tests for fatty liver disease in people with metabolic issues
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
Miami, FloridaAges 18–75 - NCT07128797RecruitingPhase 1
Safety and tolerability of B1344 injections for NAFLD
This trial tests whether multiple injections of B1344 are safe and tolerable in people with nonalcoholic fatty liver disease (NAFLD). It aims to find the right dose and check how the drug works in the body.
Beijing, Beijing MunicipalityAges 18–75 - NCT07130318Recruiting
Mediterranean diet and exercise for fatty liver in FMF
This trial tests if a Mediterranean diet plus aerobic exercise can improve fatty liver in women with Familial Mediterranean Fever (FMF) who are also obese. It aims to see if these lifestyle changes help liver health.
Dokki, Giza GovernorateAges 30–55 - NCT07149571Recruiting
New MRI for metabolic fatty liver disease
This study uses a new MRI technique to measure how metabolic fatty liver disease affects your body and to track your health over time. It aims to improve understanding of the condition and guide treatment.
Wuhan, HubeiAges Any age - NCT07193927RecruitingPhase 2
Testing a probiotic mix for fatty liver disease (MASLD)
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
Girona, GironaAges 18–75 - NCT07214870RecruitingPhase 1
A study of a new medicine for liver disease in adults with extra body weight and liver fat
This trial tests a potential new medicine (NNC4005-0001) for liver disease in adults who have extra body weight and excess fat in their liver. It aims to see if the medicine can help improve liver health.
Montreal, QuebecAges 18–69 - NCT07238985RecruitingPhase 1/Phase 2
Cilostazol for treating nonalcoholic fatty liver disease
This study tests whether a medicine called cilostazol can help treat nonalcoholic fatty liver disease. It is for adults who have fatty liver seen on an ultrasound and do not have other liver problems.
Damietta, New DamiettaAges 18–60 - NCT07241195Recruiting
Fatty Liver Study in Older Adults
This study follows older adults with fatty liver disease to understand how their metabolism changes over time and how it affects their overall health. It helps researchers learn more about the condition and its impact on the body outside the liver.
Hangzhou, ZhejiangAges 65–100 - NCT07242222RecruitingPhase 1/Phase 2
Erdosteine for non-alcoholic fatty liver disease
This trial tests whether a medicine called erdosteine can help treat non-alcoholic fatty liver disease (a condition where extra fat builds up in the liver, not caused by alcohol). It is for adults who have fatty liver confirmed by ultrasound and who do not have other serious health problems.
TantaAges 18–60
Hear when a new Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fatty liver disease?
- Yes. Clin2 currently lists 188 recruiting fatty liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fatty liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fatty liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.